Tozorakimab (formerly MEDI 3506) is a monoclonal antibody that targets interleukin-33 (IL-33) and is currently being evaluated in clinical trials as a treatment for…
Tozorakimab (formerly MEDI 3506) is a monoclonal antibody that targets interleukin-33 (IL-33) and is currently being evaluated in clinical trials as a treatment for chronic obstructive pulmonary disease. By inhibiting IL-33, this drug downregulates the RAGE and epidermal growth factor receptors.
References
Gebaseerd op: Wikipedia — Tozorakimab · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.